Physician profile
Gerald D Carp
NPI 1912963646
$3,521.10
in general payments reported to CMS, 2019-2025
19 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $66.27 · 2021: $540 · 2022: $508 · 2023: $435 · 2024: $830 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $580.30 | 2024-2025 | Tepezza |
| Abbvie INC. | $538.93 | 2022-2024 | Xen Glaucoma Treatment System, Durysta, Vuity |
| Aerie Pharmaceuticals, INC. | $366.73 | 2019-2021 | |
| Allergan, INC. | $230.57 | 2020-2022 | |
| Sight Sciences, INC. | $213.50 | 2019-2025 | Omni Surgical System |
| Alcon Vision LLC | $191.36 | 2022-2025 | Rocklatan, Rhopressa, Simbrinza |
| Glaukos Corporation | $184.76 | 2025 | Istent Infinite, Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $179.51 | 2019-2021 | |
| Horizon Therapeutics Plc | $178.42 | 2023 | Tepezza |
| Rxsight INC | $166.03 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Eyevance Pharmaceuticals LLC | $150.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $149.33 | 2019-2024 | Cequa |
| Tarsus Pharmaceuticals, INC. | $141.67 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $65.81 | 2022 | |
| Oyster Point Pharma, INC. | $65.07 | 2022-2023 | Tyrvaya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.10 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $38.14 | 2022-2025 | Vyzulta |
| Regeneron Healthcare Solutions, INC. | $18.23 | 2022 | |
| Iridex Corporation | $16.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Carp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.